MX2020007483A - Transformacion de aceites de canabidiol y terpeno en polvos secos hidrosolubles para suministro sublingual de forma solida. - Google Patents

Transformacion de aceites de canabidiol y terpeno en polvos secos hidrosolubles para suministro sublingual de forma solida.

Info

Publication number
MX2020007483A
MX2020007483A MX2020007483A MX2020007483A MX2020007483A MX 2020007483 A MX2020007483 A MX 2020007483A MX 2020007483 A MX2020007483 A MX 2020007483A MX 2020007483 A MX2020007483 A MX 2020007483A MX 2020007483 A MX2020007483 A MX 2020007483A
Authority
MX
Mexico
Prior art keywords
cannabinol
transformation
water soluble
solid form
dry powders
Prior art date
Application number
MX2020007483A
Other languages
English (en)
Inventor
John Althaus
Stephen Goldner
Original Assignee
Pure Green Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pure Green Pharmaceuticals Inc filed Critical Pure Green Pharmaceuticals Inc
Publication of MX2020007483A publication Critical patent/MX2020007483A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición incluye un compuesto de clatrato que tiene moléculas huésped y moléculas transportadoras que atrapan las moléculas huésped. Las moléculas transportadoras son un sacárido y las moléculas huésped incluyen al menos uno de un cannabinoide o un terpeno. El compuesto de clatrato incluye, en peso combinado de las moléculas transportadoras y las moléculas huésped, al menos 18% de las moléculas huésped.
MX2020007483A 2018-01-13 2019-01-11 Transformacion de aceites de canabidiol y terpeno en polvos secos hidrosolubles para suministro sublingual de forma solida. MX2020007483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862617206P 2018-01-13 2018-01-13
PCT/US2019/013126 WO2019140145A1 (en) 2018-01-13 2019-01-11 Transformation of cannabinol and terpene oils into water soluble dry powders for solid form sublingual delivery

Publications (1)

Publication Number Publication Date
MX2020007483A true MX2020007483A (es) 2020-11-12

Family

ID=67218718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007483A MX2020007483A (es) 2018-01-13 2019-01-11 Transformacion de aceites de canabidiol y terpeno en polvos secos hidrosolubles para suministro sublingual de forma solida.

Country Status (5)

Country Link
US (1) US20210077454A1 (es)
EP (1) EP3737396A4 (es)
CA (1) CA3088358A1 (es)
MX (1) MX2020007483A (es)
WO (1) WO2019140145A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028897A1 (en) * 2018-08-03 2020-02-06 Lilu's Garden, Ltd. CONSTRUCT OF β-CYCLODEXTRIN AND CANNABINOID GUEST COMPLEX AND PROCESSES FOR PRODUCING A PASTE COMPRISING THE SAME
US11975098B2 (en) 2020-05-22 2024-05-07 Colorado School Of Mines Nanosuspensions of cannabidiol for developing water-dispersible formulations
CN113244410A (zh) * 2021-05-28 2021-08-13 哈尔滨工业大学 基于多孔淀粉的增加大麻二酚水溶性的包合物制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
FI20020333A0 (fi) * 2002-02-20 2002-02-20 Tomi Jaervinen Metyloidun syklodekstriinin uudet kompleksit
RU2009100882A (ru) * 2006-06-13 2010-07-20 Карджилл, Инкорпорейтед (Us) Крупные частицы комплексов включения циклодекстринов и способы их получения
CN101574525A (zh) * 2008-05-09 2009-11-11 北京因科瑞斯医药科技有限公司 亲脂性药物羟丙基-β-环糊精包合物及其制备方法
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
WO2017183011A1 (en) * 2016-04-22 2017-10-26 Degeeter David M Water soluble cannabinoid inclusion complexes
US10058531B1 (en) * 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film

Also Published As

Publication number Publication date
EP3737396A1 (en) 2020-11-18
US20210077454A1 (en) 2021-03-18
CA3088358A1 (en) 2019-07-18
WO2019140145A1 (en) 2019-07-18
EP3737396A4 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
MX2020007483A (es) Transformacion de aceites de canabidiol y terpeno en polvos secos hidrosolubles para suministro sublingual de forma solida.
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
PH12018501059A1 (en) Tobacco composition
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
MX2019003807A (es) Derivados de oxadiazol microbiocidas.
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
CO2019001043A2 (es) Composición de cannabis
MY192703A (en) Compositions containing tucaresol or its analogs
BR112016000299A8 (pt) composições, uso de uma composição, método para o combate dos fungos fitopatogênicos e uso dos componentes
CR20210274A (es) Derivados de 2-acilaminotiazol-4-carboxamida microbicida
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
MX2007010771A (es) Anfifilos peptidicos para union a heparina angiogenicos.
EA201790064A1 (ru) Пестицидные композиции
WO2020051142A3 (en) Methods of treating cancer
CL2019000198A1 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
BR112018013985A2 (pt) glicosídeos de esteviol altamente solúveis
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
MX2017005877A (es) Uso de 3,3'-dimetoxi-4, 4'-dihidroxiestilbenos como una sustancia saborizante.
MX2018014382A (es) Atrayentes para roedores.
EA202090732A1 (ru) Составы для трансдермального введения
PH12018501509A1 (en) Laundry product
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
WO2018156448A8 (en) Prediction and treatment of immunotherapeutic toxicity